Selegiline
Indications
Selegiline is used for:
Parkinson Diseas
Adult Dose
Oral
Early parkinsonism
Adult: As conventional preparation: 10 mg daily, either as a single dose (in the morning) or in 2 divided doses of 5 mg (at breakfast and lunchtime). As oral lyophilisate tab: Initially, 1.25 mg daily.
Hepatic Impairment
Use caution; safety and efficacy not established
Child Dose
Safety and efficacy not established
Renal Dose
Renal Impairment
Use caution; safety and efficacy not established
Administration
Should be taken with food.
Contra Indications
Active duodenal or gastric ulcer. Concomitant use w/ serotonin agonists (e.g. sumatriptan, zolmitriptan), pethidine and other opioids, antidepressants (including TCAs, MAOIs, SSRIs, serotonin norepinephrine reuptake inhibitors), St John's wort.
Precautions
Patient w/ uncontrolled HTN, angina, arrhythmias, psychosis, history of peptic ulcer and those at risk of orthostatic hypotension. Severe hepatic or renal impairment. Elderly. Pregnancy and lactation. Patient Counselling This drug may cause somnolence, if affected, do not drive or operate machinery. Monitoring Parameters Monitor BP, symptoms of parkinsonism, suicidal ideation, general mood and behaviour. Perform periodic skin examinations.
Lactation: unknown; use caution
Pregnancy-Lactation
Interactions
May increase risk of hypertensive reactions w/ dopamine. May increase bioavailability w/ OCs or drugs for hormone replacement therapy.
Potentially Fatal: May cause severe serotonin syndrome w/ antidepressants (including TCAs, MAOIs, SSRIs, serotonin norepinephrine reuptake inhibitors), serotonin agonists (e.g. sumatriptan, zolmitriptan). May cause resp depression and hypotension w/ pethidine and other opioids.
Adverse Effects
Side effects of Selegiline :
>10%
Dyskinesia
Nausea (20%)
1-10%
Abdominal pain,Dry mouth
Frequency Not Defined (selected)
Arrhythmias,Confusion,EPS,Generalized pain,Hallucinations,Headache,HTN,Insomnia,Mood changes,Orthostatic hypotension,Syncope,Urinary retention,Vomiting
Mechanism of Action
Selegiline increases dopaminergic activity by intervening w/ the reuptake of dopamine at the synapse. It also irreversibly inhibits monoamine oxidase (MAO)-B which is involved in the metabolism of dopamine in the brain.